Home – Neurimmune

Transforming the wisdom of life

into promising drug candidates

Neurimmune’s scientists discovered with the Reverse Translational Medicine technology the anti-ATTR antibody Cliramitug (formerly ALXN2220, NI006) for ATTR cardiomyopathy, the anti-SOD1 antibody AP-101 for ALS and the anti-NogoA antibody NG004 for spinal cord injury. These programs are currently evaluated in clinical trials.

Neurimmune pipeline

Decoding immune memories of life

to develop therapeutic antibodies

By using Reverse Translational Medicine™ technology, Neurimmune’s scientists and researchers translate genetic information of lymphocyte transcripts from elderly human donors into therapeutic antibodies. Evolutionarily optimized and wisely elected antibodies with preferred activities combine high affinity with target selectivity, excellent pharmacodynamics and low immunogenicity.

RTM™ Technology Platform

Scientific publications

View all

N Engl J Med - 2023

Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid

Sci Transl Med. - 2018

A human-derived antibody targets misfolded SOD1 and ameliorates motor symptoms in mouse models of amyotrophic lateral sclerosis

Nature - 2016

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

News

View all

13.01.2026 | Company News

Neurimmune today announced that the company joined the ACCESS-AD consortium, a new European initiative to accelerate the implementation of scientific innovations for Alzheimer’s disease (AD) management in real-world health systems.

07.01.2026 | Press Release

AL-S Pharma will present at the upcoming J. P. Morgan 2026 Annual Healthcare Conference on Thursday, January 15, 2026.

05.12.2025 | Press Release

AL-S Pharma today presented its Phase 2 clinical study results on AP-101 at the 36th International Symposium on ALS/MND in San Diego.

Driven by the passion for life

to help patients around the world